Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review

References

• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–6. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–36. doi:10.1038/s41586-020-2521-4.
   PubMed Web of Science ®Google Scholar
• Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1167–69. doi:10.15585/mmwr.mm7034e4.
   PubMed Web of Science ®Google Scholar
• Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R, et al. Effectiveness of Pfizer-BioNtech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1163–66. doi:10.15585/mmwr.mm7034e3.
   PubMed Web of Science ®Google Scholar
• FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations. The U.S. Food and Drug Administration.
   Google Scholar
• COVID-19 Vaccine Booster Shots. Centers for Disease Control and Prevention.
   Google Scholar
• Young-Xu Y, Korves C, Roberts J, Powell EI, Zwain GM, Smith J, Izurieta HS. Coverage and estimated effectiveness of mRNA COVID-19 vaccines among US veterans. JAMA Netw Open. 2021;4:e2128391. doi:10.1001/jamanetworkopen.2021.28391.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, Shapiro NI, Ginde AA, Douin DJ, Prekker ME, et al. Effectiveness of Pfizer-BioNtech and moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:674–79. doi:10.15585/mmwr.mm7018e1.
   PubMed Web of Science ®Google Scholar
• Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, Patel K, Anglin O, Reingold A, Chai SJ, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 years - COVID-NET, 13 States, February-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1088–93. doi:10.15585/mmwr.mm7032e3.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M, and McNeal T , et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. Clin Infect Dis. 2021;ciab687. doi:10.1093/cid/ciab687.
   Google Scholar
• Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, DeSilva, MB, Natarajan, K, Bozio, CH, Lewis, N, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385:1355–71. doi:10.1056/NEJMoa2110362.
   PubMed Web of Science ®Google Scholar
• Bajema KL, Dahl RM, Prill MM, Meites E, Rodriguez-Barradas MC, Marconi VC. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalization - five veterans affairs medical centers, United States, February 1-August 6, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1294–99. doi:10.15585/mmwr.mm7037e3.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray S, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet (London, England). 2021;398:1407–16. doi:10.1016/S0140-6736(21)02183-8.
   PubMed Web of Science ®Google Scholar
• Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, and Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science (New York, NY). 2021;375:331–336.
   Google Scholar
• Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–82. doi:10.1056/NEJMc2032195.
   PubMed Web of Science ®Google Scholar
• Bates TA, Leier HC, Lyski ZL, Goodman JR, Curlin ME, Messer WB, Tafesse FG. Age-Dependent neutralization of SARS-CoV-2 and P.1 variant by vaccine immune serum samples. Jama. 2021;326(9):868–69. doi:10.1001/jama.2021.11656.
   PubMed Web of Science ®Google Scholar
• Collier DA, Ferreira I, Kotagiri P, Datir RP, Lim EY, Touizer E, Meng B, Abdullahi A, Elmer A, Kingston N, et al. Age-Related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–22. doi:10.1038/s41586-021-03739-1.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMoa2114583.
   PubMed Web of Science ®Google Scholar
• Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, and Rabl D, et al. Age-Dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021;73:2065–2072.
   PubMed Web of Science ®Google Scholar
• Massachusetts’ COVID-19 vaccination phases. Commonwealth of Massachusetts.
   Google Scholar
• Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-Based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457–66.e4. doi:10.1016/j.cell.2021.12.033.
   PubMed Web of Science ®Google Scholar
• Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Berrios C, Ofoman O, Chang CC, and Hauser BM, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2012;22:757–773.
   Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. Jama. 2022;327(7):639. doi:10.1001/jama.2022.0470.
   PubMed Web of Science ®Google Scholar
• Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J, Bhiman JN, Scheepers C, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet (London, England). 2022;399:437–46. doi:10.1016/S0140-6736(22)00017-4.
   PubMed Web of Science ®Google Scholar